Essais liés11clinical trials
VilleCopenhagenlocalisation
PaysDenmarklocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05748171

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Sotorasib Cancer Phase 3 NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) RECRUITING
AOC 1001 (del-desiran) Myopathies Phase 3 NCT06411288 HARBOR — Global Study of Del-desiran for the Treatment of DM1 COMPLETED
Inotuzumab ozogamicin Cancer Phase 2 NCT05748171 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL RECRUITING
Efgartigimod IV Myasthénie Phase 3 NCT06298552 ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Del-desiran (AOC 1001) Myopathies Phase 3 NCT07008469 HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 ENROLLING_BY_INVITATION
AOC-1020 Myopathies Phase 3 NCT07038200 FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD RECRUITING
Sevasemten 10 mg Myopathies Phase 2 NCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) ACTIVE_NOT_RECRUITING
Sevasemten Myopathies Phase 2 NCT06066580 MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy ENROLLING_BY_INVITATION
Nipocalimab Lupus Phase 3 NCT07438496 GARDENIA-SLE — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus RECRUITING
Physical Activity and Fatigue in Myasthenia Gravis Myasthénie À vérifier NCT03905473 Physical Activity and Fatigue in Myasthenia Gravis COMPLETED
Efgartigimod PH20 SC Myasthénie Phase 3 NCT06558279 ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis ACTIVE_NOT_RECRUITING